Cross-pharmacology analysis of G protein-coupled receptors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 15, 2011, Pages 1956-1963

  Briansó, Ferran ^a   Carrascosa, Maria C ^a   Oprea, Tudor I ^b   Mestres, Jordi ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Drug repositioning; GPCR network; Ligand similarity; Target profile

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MUSCARINIC RECEPTOR;

ARTICLE; BINDING AFFINITY; CROSS-PHARMACOLOGY ANALYSIS; DRUG TARGETING; LIGAND BINDING; PROTEIN ANALYSIS;

DATABASES, FACTUAL; DRUG DESIGN; DRUG DISCOVERY; GENOMICS; HUMANS; LIGANDS; PHARMACOLOGY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79960606838     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796391285     Document Type: Article

References (56)

1. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 2004, 103, 21-80.
2. Jacoby, E.; Bouhelal, R.; Gerspaher, M.; Seuwen, K. The 7TM G protein-coupled receptor target family. ChemMedChem 2006, 1, 760-782.
3. Vassilatis, D. K.; Hohmann, J. G.; Zeng, H.; Li, F.; Ranchalis, J. E.; Mortrud, M. T.; Brown, A.; Rodriguez, S. S.; Weller, J. R.; Wright, A. C.; Bergmann, J. E.; Gaitanaris, G. A. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA 2003, 100, 4903-4908.
4. Chung, S.; Funakoshi, T.; Civelli, O. Orphan GPCR research. Br. J. Pharmacol. 2008, 153, S339-S346.
5. Levoye, A.; Jockers, R. Alternative drug discovery approaches for orphan GPCRs. Drug Discov. Today 2008, 13, 52-58.
6. Strachan, R. T.; Ferrara, G.; Roth, B. L. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov. Today 2006, 11, 708-716.
7. Savchuk, N. P.; Balakin, K. V.; Tkachenko, S. E. Exploring the chemogenomic knowledge space with annotated chemical libraries. Curr. Opin. Chem. Biol. 2004, 8, 412-417.
8. Balakin, K. V.; Tkachenko, S. E.; Lang, S. A.; Okun, I.; Ivash- chenko, A. A.; Savchuk, N. P. Property-based design of GPCR-targeted library. J. Chem. Inf. Comput. Sci. 2002, 42, 1332-1342.
9. Lowrie, J. F.; Delisle, R. K.; Hobbs, D. W.; Diller, D. J. The differ- ent strategies for designing GPCR and kinase targeted libraries. Comb. Chem. High Throughput Screen. 2004, 7, 495-510.
10. Klabunde, T.; Hessler, G. Drug design strategies for targeting G protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
11. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structures by G protein-coupled receptors. J. Med. Chem. 2004, 47, 888-899.
12. van der Horst, E.; Okuno, Y.; Bender, A.; Ijzerman, A. P. Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner. J. Chem. Inf. Model. 2009, 49, 348-360.
13. Gregori-Puigjané, E.; Mestres, J. Coverage and bias in chemical library design. Curr. Opin. Chem. Biol. 2008, 12, 359-365.
14. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 2004, 3, 353-359.
15. Gregori-Puigjané, E.; Mestres, J. A ligand-based approach to mining the chemogenomic space of drugs. Comb. Chem. High Throughput Screen. 2008, 11, 669-676.
16. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009, 4, 680-686.
17. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R. V. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol. BioSys. 2009, 5, 1051-1057.
18. Surgand, J.-S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A che-mogenomic analysis of the transmembrane binding cavity of human G protein-coupled receptors. Proteins 2006, 62, 509-538.
19. Jacob, L.; Hoffmann, B.; Stoven, V.; Vert, J.-P. Virtual screening of GPCRs: an in silico chemogenomics approach. BMC Bioinfor-matics 2008, 9, 363.
20. Weill, N.; Rognan, D. Development and validation of a novel pro-tein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J. Chem. Inf. Model. 2009, 49, 1049-1062.
21. Heilker, R.; Wolff, M.; Tautermann, C. S.; Bieler, M. G protein-coupled receptor-focused drug discovery using a target class platform approach. Drug Discov. Today 2009, 14, 231-240.
22. Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Garland, S. L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem. 2009, 52, 4429-4442.
23. van der Horst, E.; Peironcely, J. E.; Ijzerman, A. P.; Beukers, M. W.; Lane, J. R.; van Vlijmen, H. W. T.; Emmerich, M. T. M.; Okuno, Y.; Bender, A. A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinformatics 2010, 11, 316.
24. Hert, J.; Keiser, M. J.; Irwin, J. J.; Oprea, T. I.; Shoichet, B. K. Quantifying the relationships among drug classes. J. Chem. Inf. Model. 2008, 48, 755-765.
25. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 2006, 24, 805-815.
26. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007, 25, 197-206.
27. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L. H.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature 2009, 462, 175-182.
28. Garcia-Serna, R.; Mestres J. Anticipating drug side effects by comparative pharmacology. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1253-1263.
29. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R. V. Data completeness: the Achilles heel of drug-target networks. Nat. Bio-technol. 2008, 26, 983-984.
30. Oprea, T. I. Chemical space navigation in lead discovery. Curr. Opin. Chem. Biol. 2002, 6, 384-389.
31. Krejsa, C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. De-vel. 2003, 6, 470-480.
32. Olah, M.; Mracec, M.; Ostopovici, L.; Rad, R.; Bora, A.; Hada-ruga, N.; Olah, I.; Banda, M.; Simon, Z.; Oprea, T.I. WOMBAT: World of Molecular Bioactivity. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed.; Wiley-VCH: New York, 2004; pp. 223-239.
33. MDL Drug Data Report database. MDL Information Systems, Inc. http://mdl.com.
34. Okuno, Y.; Tamon, A.; Yabuuchi, H.; Niijima, S.; Minowa, Y.; Tonomura, K.; Kunimoto, R.; Feng, C. GLIDA: GPCR ligand database for chemical genomics drug discovery - database and tools update. Nucl. Acids Res. 2008, 36, D907-D912.
35. Jensen, N. H.; Roth, B. L. Massively parallel screening of the re-ceptorome. Comb. Chem. High Throughput Screen. 2008, 11, 420-427. Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract HHSN-271-2008-00025-C. http://pdsp.med.unc.edu.
36. Liu, T.; Lin, Y.; Wen, X.; Jorrisen, R. N.; Gilson, M. K. Bind-ingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucl. Acids Res. 2007, 35, D198-D201. http://www.bindingdb.org.
37. Harmar, A. J.; Hills, R. A.; Rosser, E. M.; Jones, M.; Buneman, O. P.; Dunbar, D. R.; Greenhill, S. D.; Hale, V. A.; Sharman, J. L.; Bonner, T. I.; Catterall, W. A.; Davenport, A. P.; Delagrange, P.; Dollery, C. T.; Foord, S. M.; Gutman, G. A.; Laudet, V.; Neubig, R. R.; Ohlstein, E. H.; Olsen, R. W.; Peters, J.; Pin, J. P.; Ruffolo, R. R.; Searls, D. B.; Wright, M. W.; Spedding, M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucl. Acids Res. 2009, 37, D680-D685. http://www.iuphar-db.org.
38. Wang, Y.; Bolton, E.; Dracheva, S.; Karapetyan, K.; Shoemaker, B. A.; Suzek, T. O.; Wang, J.; Xiao, J.; Zhang, J.; Bryant, S. H. An overview of the PubChem bioassay resource. Nucl. Acids Res. 2010, 38, D255-D266. http://pubchem.ncbi.nlm.nih.gov/.
39. ChEMBLdb database. http://www.ebi.ac.uk/chembldb.
40. hGPCR-lig database. http://bioinfo-pharma.u-strasbg.fr/hGPCR-lig.
41. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901-D906. http://www.drugbank.ca/.
42. Daylight Toolkit. Daylight, Inc. http://www.daylight.com.
43. Unity. Tripos, Inc. http://www.tripos.com.
44. Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimi-zation of MDL keys for use in drug discovery. J. Chem. Inf. Model. 2002, 42, 1273-1280.
45. Pipeline Pilot. Accelrys, Inc. http://www.accelrys.com.
46. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. Scaffold hopping by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. 1999, 38, 2894-2896.
47. Jenkins, J. L.; Glick, M.; Davies, J. W. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new che-motypes. J. Med. Chem. 2004, 47, 6144-6159.
48. Wörlein, M.; Meinl, T.; Fischer, I.; Philippsen, M. A quantitative comparison of the subgraph miners MoFa, gSpan, FFSM, and Gaston. Knowledge Discov. Datab. 2005, 392-403.
49. Gregori-Puigjané, E.; Mestres, J. SHED: Shannon entropy descriptors from topological feature distributions. J. Chem. Inf. Model. 2006, 46, 1615-1622.
50. Shannon, C. E.; Weaver, W. The Mathematical Theory of Communication, University of Illinois, Urbana, 1949.
51. Broccatelli, F.; Carosati, E.; Cruciani, G.; Oprea, T. I. Transporter-mediated efflux influences CNS side effects: ABCB1, from antitar-get to target. Mol. Inf. 2010, 29, 16-26.
52. Van Zwieten, P. A.; Doods, H. N. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovascular Drugs Ther. 1995, 9, 159-167.
53. Zhang, J.; Abdel-Rahman, A. A. Nischarin as a functional imida-zoline I1 receptor. FEBS Lett. 2006, 580, 3070-3074.
54. Mustafi, D.; Palczewski, K. Topology of class A G protein-couple receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. Mol. Pharmacol. 2009, 75, 1-12.
55. Congreve, M.; Marshall, F. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharmacol. 2010, 159, 986-996.
56. Morphy, R.; Rankovic, Z. Designed multiple ligands: an emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6524-6543.